AstraZeneca\'s Lynparza meets main goal in latestage prostate cancer study

AstraZeneca's Lynparza meets main goal in late-stage prostate cancer study

03:48 EDT 7 Aug 2019 | Reuters

British drugmaker AstraZeneca said on Wednesday its cancer drug Lynparza has met the main goal of a late-stage study in patients with metastatic prostate cancer and have certain genetic mutations.

More From BioPortfolio on "AstraZeneca's Lynparza meets main goal in late-stage prostate cancer study"